T1	Participants 42 126	federally-funded citalopram trial in children with pervasive developmental disorders
T2	Participants 144 292	Advance Autism Research and Treatment Network conducted a randomized trial with citalopram in children with Pervasive developmental disorders (PDDs)
T3	Participants 379 566	Subjects (128 boys, 21 girls) had a mean age of 9.3 (Â±3.12) years; 132 (88.6%) were diagnosed with autistic disorder (4.7% with Asperger's Disorder; 6.7% with PDD-not otherwise specified)
T4	Participants 568 717	Less than half of the subjects were intellectually disabled; 117 (78.5%) were rated Moderate or Marked on the Clinical Global Impression for Severity
